Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib

Clinica Chimica Acta

Volumn 440, Issue , 2015, Pages 44-48

  Song, Gaoguang ^a   Liu, Yujie ^a   Wang, Yanying ^a   Ren, Guanjun ^b   Guo, Shuai ^a   Ren, Junling ^a   Zhang, Li ^b   Li, Zhili ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Immunoinflammation related protein complexes; Non small cell lung cancer; Progression free survival; Time length of disease progression; Time length of humoral immune and inflammatory response

Indexed keywords

APOLIPOPROTEIN A1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C7; COMPLEMENT FACTOR H; HAPTOGLOBIN; ICOTINIB; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G1; TRANSFERRIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CROWN ETHER; PLASMA PROTEIN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; DRUG MONITORING; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PERSONALIZED MEDICINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCEDURES; TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; DISEASE PROGRESSION; DRUG MONITORING; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNITY, HUMORAL; INDIVIDUALIZED MEDICINE; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; TIME FACTORS;

EID: 84913529433     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.11.010     Document Type: Article

References (17)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2013, 63:11-30.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
3. Pallis A.G., Syrigos K.N. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer 2013, 80:120-130.
4. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
5. Tartarone A., Lazzari C., Lerose R., Conteduca V., Improta G., Zupa A., et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer 2013, 81:328-336.
6. Onitsuka T., Uramoto H., Nose N., Takenoyama M., Hanagiri T., Sugio K., et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010, 68:198-203.
7. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
8. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
9. Guttman-Yassky E., Mita A., De Jonge M., Matthews L., McCarthy S., Iwata K.K., et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010, 46:2010-2019.
10. Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
11. Hanash S.M., Baik C.S., Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011, 8:142-150.
12. Yamaguchi H., Soda H., Nakamura Y., Takasu M., Tomonaga N., Nakano H., et al. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2011, 67:331-338.
13. Wang Y.Y., Song G.G., Wang Y.M., Qiu L., Qin X.Z., Liu H., et al. Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer. J Proteome Res 2014, 13:710-719.
14. Ren G.J., Zhao Y.Y., Zhu Y.J., Xiao Y., Xu J.S., Shan B., et al. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J (Engl) 2011, 124:19-25.
15. Shi Y., Zhang L., Liu X., Zhou C., Zhang S., Wang D., et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013, 14:953-961.
16. O'Byrne K., Paz-Ares L., Pereira J.R., von Pawel J., Ramlau R., Storkel S., et al. Epidermal growth factor receptor (EGFR) expression as a predictive biomarker of survival in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line therapy with cetuximab combined with chemotherapy in the FLEX trial. Eur J Cancer 2011, 47:S591-S91.
17. Dahabreh I.J., Linardou H., Kosmidis P., Bafaloukos D., Murray S. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 2011, 22:545-552.